Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Koda-Kimble MA, Lloyd YL, et al. In: Alldredge BK, Corelli RL, Ernst ME, Guglielmo BJ, Jacobson PA, Kradjan WA, et al., editors. Koda-Kimble & Young’s Applied Therapeutics, The clinical use of drugs. 10th ed. Philadelphia: Lippincott Williams and Wilkins; 2012. p. 1672–89.
2. Mohammed HB, Yismaw MB, Fentie AM, Tadesse TA. Febrile neutropenia management in pediatric cancer patients at Ethiopian Tertiary Care Teaching Hospital. BMC Res Notes. 2019;12(1):1–6. https://doi.org/10.1186/s13104-019-4569-5.
3. Klastersky J, De Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropenia ESMO clinical practice guidelines. Ann Oncol. 2016;27((suppl_ 5)):v111-8.
4. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2006;57(2):176–89. https://doi.org/10.1093/jac/dki448.
5. Friedman H, Specter S, Watanabe M, Pan SH. Tumor-induced immunosuppression. Am J Pathol. 1978;93(2):499–514.